Partial AUCs in Long-Acting Injectables: Rationale, Challenges, Variability, Usefulness, and Clinical Relevance
Regulatory authorities typically require bioequivalence to be demonstrated by comparing pharmacokinetic parameters like area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C<sub>max</sub>). Because in certain cases, AUC and C<sub>max</sub> alone may not be adequate...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2024-12-01
|
| Col·lecció: | Pharmaceutics |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/1999-4923/17/1/21 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|